Anti-Fibrinolytic Drugs - China | Statista Market Forecast

The Anti-Fibrinolytic Drugs market in China is projected to reach a revenue of US$1.90bn in 2024.
It is expected to show an annual growth rate (CAGR 2024-2029) of 5.32%, resulting in a market volume of US$2.47bn by 2029.
When compared globally, United States is predicted to generate the highest revenue with US$9.86bn in 2024.
China's robust pharmaceutical industry is driving the demand for anti-fibrinolytic drugs, as the country experiences a rise in cardiovascular diseases.

Definition:
The Anti-Fibrinolytics market covers drugs which help blood to clot. They are used to treat and prevent bleeding episodes of patients with hemophilia. Moreover, anti-fibrinolytics are used before or during certain surgeries. In doing so, the usage of blood products, such as fresh frozen plasma, as well as the associated risks of infections and/or anaphylactic reactions can be avoided.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Roche, Takeda, Novo Nordisc, Sanofi, Bayer

Inhibitors of fibrinolysis
Drugs to treat hemophilia

Anti-coagulants
Anti-hypertensives
Wound care

Anti-Fibrinolytic Drugs, also known as hemostatic agents, are used to control bleeding by preventing the breakdown of blood clots. In China, the Anti-Fibrinolytic Drugs market has been steadily growing in recent years.

Customer preferences: Chinese customers prefer Anti-Fibrinolytic Drugs due to their effectiveness in controlling bleeding during surgery and reducing the need for blood transfusions. Additionally, the increasing number of surgeries being performed in China has led to a higher demand for these drugs.

Trends in the market: One of the major trends in the Anti-Fibrinolytic Drugs market in China is the increasing adoption of these drugs in various surgical procedures, including cardiac surgeries, orthopedic surgeries, and liver surgeries. This trend is expected to continue as the number of surgeries being performed in China is projected to increase in the coming years.Another trend in the market is the development of new and improved Anti-Fibrinolytic Drugs. Pharmaceutical companies are investing in research and development to create more effective and safer drugs, which are expected to further drive market growth.

Local special circumstances: China has a large population with a high incidence of cardiovascular diseases, which has led to an increase in the number of cardiac surgeries being performed. Additionally, the aging population in China has also contributed to the growth of the Anti-Fibrinolytic Drugs market, as older adults are more likely to require surgery and are at a higher risk of bleeding complications.

Underlying macroeconomic factors: The Chinese government's focus on improving healthcare infrastructure and increasing access to medical care has also contributed to the growth of the Anti-Fibrinolytic Drugs market. Additionally, the increasing disposable income of the Chinese population has led to a higher demand for quality healthcare services, including surgical procedures and related medications.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

Bleeding disorders affect the clotting of blood and can result in excessive bleeding inside and outside of the body. Bleeding disorders are almost always inherited and common symptoms include easy bruising, frequent nosebleeds, heavy menstrual bleeding, and excessive bleeding from small cuts. Treatments vary depending on the type of disorder, but may include factor replacement therapy, iron supplementation, topical products or sprays, or blood transfusions. The most common types of bleeding disorders are hemophilia A and B and von Willebrand disease. In 2022, there were around 257,146 people worldwide who had been diagnosed with hemophilia and 100,505 who had been diagnosed with von Willebrand disease.